Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012
(Thomson Reuters ONE) -
Not intended for US media
Oslo, Norway, 16 May 2012 - Algeta ASA (OSE: ALGETA), a company focused on the
development of novel targeted cancer therapeutics, announces that further data
from the phase III ALSYMPCA study of Alpharadin (radium-223 chloride) will be
presented at the 48th Annual Meeting of the American Society of Clinical
Oncology (ASCO), 1-5 June (Chicago, IL, USA).
Details of the presentations, including an oral presentation of a Late-breaking
Abstract, are as follows:
Final overall survival analysis results from the phase III, double-blind,
randomized, multinational study of radium-223 chloride (Alpharadin) in the
treatment of patients with castration-resistant prostate cancer (CRPC) with bone
metastases (ALSYMPCA)
Late-Breaking Abstract #LBA4512, Oral Abstract Session: Genitourinary (Prostate)
Cancer
Tuesday, 5 June, 10:45 a.m. - 11:00 a.m., E Arie Crown Theater
Presented by Dr. Christopher Parker (Institute of Cancer Research and Royal
Marsden Hospital, Sutton, UK), Principal Investigator for ALSYMPCA.
Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) & ECOG
performance status (PS) in patients with castration-resistant prostate cancer
(CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA)
Abstract #4551, Poster Discussion: Genitourinary (Prostate) Cancer Poster
Session
Monday, 4 June, 8:00 a.m. - 12:00 p.m., E450A, Poster Board 5
Poster Discussion: Monday, 4 June 11:30 a.m. - 12:30 p.m., E Arie Crown Theater
Presented by Dr. Oliver Sartor, Medical Director Tulane Cancer Center, Tulane
Medical School and Principal Investigator of the US arm of ALSYMPCA
Presentations and posters will be available to download at www.algeta.com
following these sessions.
###
For further information, please contact
Mike Booth +47 2202 4510
Communications & Corporate Affairs ir(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is being evaluated as a
potential new treatment for cancer patients with bone metastases. Alpharadin is
under clinical investigation in castration-resistant prostate cancer (CRPC)
patients with bone metastases. Submissions seeking marketing approval for this
indication are expected to be made in mid 2012 to regulatory authorities in both
the United States and Europe; Alpharadin has Fast Track designation for this
indication in the US. Alpharadin, which is exclusively licensed to Bayer, is not
currently approved by the US Food & Drug Administration (FDA), the European
Medicines Agency (EMA) or any other health authority.
Alpharadin is also under clinical investigation in endocrine-refractory breast
cancer patients with bone metastases and is in a phase I/IIa trial in
combination with docetaxel chemotherapy in CPRC patients with bone metastases.
Alpharadin is being evaluated and will be commercialized, if approved, under a
global agreement with Bayer Pharma AG. If approved, Bayer will market Alpharadin
worldwide, and Algeta will co-promote Alpharadin with Bayer in the US.
Algeta is also evaluating the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a potential future pipeline of tumor-targeting alpha-
pharmaceutical candidates. Algeta has TTC agreements in place with Sanofi and
Affibody.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statements
This news release contains certain forward-looking statements based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance to the correctness of such
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements. These factors include, among other things,
unforeseen delays in the timing of expected regulatory filings, risks or
uncertainties associated with the success of future clinical trials,
collaborations with other companies in the development of targeting molecules
and alpha particle payloads, the ability to identify and hire a sufficient
number of qualified employees for the US field force, growth management, general
economic and business conditions and the pricing environment, the impact of
competition, the ability to successfully commercialize Alpharadin and our other
products, the risk that costs associated with the co-promotion of Alpharadin may
be greater than anticipated, the risk that research & development will not yield
new products that achieve commercial success, manufacturing capacity, the risk
of non-approval of patents not yet granted, risks in obtaining regulatory
approvals for Alpharadin and our other products and difficulties of obtaining
relevant governmental approvals for new products, and the other risks and
uncertainties described in our annual report.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release:
http://hugin.info/134655/R/1612664/513404.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1612664]
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2012 - 14:05 Uhr
Sprache: Deutsch
News-ID 147322
Anzahl Zeichen: 7412
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
